Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.
While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.
Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.
In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.
Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.
The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020-2030.
Biosimilar drugs (or biosimilars), used in management of several disease conditions, account for about 25% of global pharmaceutical industry.
Adoption of biosimilar drugs among patients having cancer has triggered significant advancements in cancer treatments and supportive care.
The US FDA has approved various biosimilars for treatment of cancer and supportive care management, and the figure is expected to follow a positive trend.
Further, usage of biosimilars is associated with exponential cost-savings. Recent studies stress that biosimilars will result in a reduction of US$ 54 Bn in direct expenditure on biologic drugs over 2017-2026, or around 3% of overall anticipated biologic spending within the same timeframe, ranging of US $24-150 Bn.
Prominent drivers of cost savings include number and timing of biosimilars in development and marketing, acceptability of usage among prescribers and patients, cost of biosimilar development, changes in global market size, cost-sharing, payer coverage, and other regulatory policies.
Although these figures appear promising, the expected cost savings with usage of biosimilars are projected to remain modest.
Globally, the cost of biosimilars is about 20-30% less compared to that of reference drugs. The cost savings will bank on several factors such as cost of reference drugs, their sales, and degree of competition.
Principal Consultant
Among the distribution channels, hospital pharmacies are expected to generate greater total return to shareholders (TRS) – over 50% of overall cancer supportive care products market revenue.
About 33% of overall healthcare companies are looking forward to transmuting their whole business model in 2020, with hospitals, the major providers of cancer care, accounting for 66% of them.
Pharmacy is an ever-evolving landscape, as such, hospital pharmacies are striving to keep pace with surging demand for cancer supportive care products and consistent rise in healthcare expenses. With inbound costs of oncology drugs, hospital pharmacies are in a constant juggle to reduce expenses and keep the budget on track.
Hospital pharmacies are monitoring trends on cancer supportive care products that have measurable effect on pharmacy budget in order to ensure maximum savings for hospitals’ pharmaceutical expenses.
While hospital pharmacies continue to capture a bigger slice of cancer supportive care products market value, players are also unlocking new revenue lines in retail pharmacies.
Regionally, North America continues to engage manufacturers of cancer supportive care products over the following decade. Cancer is the major cause of mortality in Canada and the second-leading cause, after cardiovascular diseases (CVD), in the US.
Consequently, governments in the US and Canada are substantially investing in cancer research and development of pharmaceutical drugs, especially erythropoietin stimulating agents, and granulocyte colony stimulating factors.
Moreover, the regulatory authorities have been showing immediacy in approving various cancer supportive care products. The US has granted approval to around 23 biosimilars by July 2019, of which 14 carry indications for use in oncology.
In a similar vein, Asia Pacific (APAC) is also offering value-capture opportunities for players in of cancer supportive care products market.
Studies reveal that nearly half of the global cancer cases are reported in APAC, and by 2030, the number of individuals fighting cancer is likely to soar by about 35%, with mortality increasing by about 40%.
Biopharmaceutical companies in APAC are beginning to launch APAC-centric clinical therapeutics research. Within oncology domain, major portion of APAC drug development is centered on breast, lung, and colorectal cancers. Carrying an enormous cancer burden, the oncology drug market in China is expected to hit US$ 18 Bn by 2023.
Driven by expanding healthcare needs in tandem with supportive government policies. APAC represents tremendous opportunity for cancer supportive care product manufacturers. Countries are implementing steps to set up domestic environments that can leverage local talent and fetch foreign investment.
The cancer supportive care products market is witnessing the penetration of emerging players both at local and international level. The rising level of market competition is making new product launches, innovative applications, and tech-enabled developments a key priority among market players. Some of these include,
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Recent medical studies are underway unleashing the potential of cannabis or cannabidiol (CBD) in cancer treatment. With limited number of opportunities for cancer treatment currently, CBD is likely to hold great promise for both patients and scientists in addressing the situation.
Given its cytotoxic, antiemetic, and anti-inflammatory effects, CBD has been garnering huge attention to its possible usage as a potent anti-cancer agent.
While regulatory bodies in the US have prohibited cannabis consumption, several states in the US, as well as some countries across the globe have legalized cannabis consumption for medical applications.
Two CBD drugs have been approved by the US Food and Drug Administration (FDA) - nabilone and dronabinol were researched as potent antiemetic medications.
Research and trials are in progress, incorporating swathes of scientists worldwide scrutinizing the potential of CBD for cancer treatment. However, these studies are yet to discover ample concrete scientific evidence to prove the safety and efficacy of CBD oil in treating cancer.
These scientific studies and research have been performed using animals or cancer cells developed in the laboratories. Human beings are more complex compared to animals, as such, results elaborated after the studies might not work as effectively for humans as they did in animal trials.
At present, the loopholes in research studies regarding consumption of CBD oil are creating hindrance for its approval as a potential medication for cancer treatment
Drug Class
Indication
Distribution Channel
Region
The cancer supportive care products market is likely to secure a CAGR of 2.5% through 2032.
The cancer supportive care products market size is estimated to cross US$ 26.41 Bn by 2032.
The cancer supportive care products market is likely to record a value of US$ 20.63 Bn in 2022.
North America is likely to lead the cancer supportive care products market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Market Trends
3.2. Key Product/Development Trends
4. Key Success Factors
4.1. Parent Market Overview
4.2. PEST
4.3. Regulations
4.4. Key Promotional Strategies, By Key Manufacturers
5. Global Market Demand (in Volume) Analysis 2015-2019 and Forecast, 2020-2030
5.1. Historical Market Volume Analysis, 2015-2019
5.2. Current and Future Market Volume Projections, 2020-2030
5.3. Y-o-Y Growth Trend Analysis
6. Global Market - Pricing Analysis
6.1. Regional Pricing Analysis By Drug Class
6.2. Pricing Break-up
6.2.1. Manufacturer Level Pricing
6.2.2. Distributor Level Pricing
6.3. Global Average Pricing Analysis Benchmark
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2015–2019 and Forecast, 2020–2030
7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Healthcare Expenditure Outlook
8.2. Forecast Factors - Relevance & Impact
8.2.1. Average Product Cost of Cancer Supportive Care Products
8.2.2. Frequency of Product Launches
8.2.3. Per Patient Spending
8.2.4. Product Awareness
8.2.5. Regulatory Approval Timeline
8.3. Value Chain
8.4. Market Dynamics
8.4.1. Drivers
8.4.2. Restraints
8.4.3. Opportunity Analysis
9. COVID19 Crisis Analysis
9.1. Current COVID19 Statistics and Probable Future Impact
9.2. Current GDP Projection and Probable Impact
9.3. Current Economic Projection as compared to 2008 Economic analysis
9.4. COVID19 and Impact Analysis
9.4.1. Revenue By Drug Class
9.4.2. Revenue By Country
9.5. 2020 Market Scenario
9.6. Quarter by Quarter Forecast
9.7. Projected recovery Quarter
9.8. Recovery Scenario – Short term, Midterm and Long Term Impact
10. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis By Drug Class , 2015 - 2019
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Drug Class, 2020 - 2030
10.3.1. Nonsteroidal Anti- Inflammatory Drugs
10.3.2. Anti-Infective
10.3.3. Anti-Emetics
10.3.4. Monoclonal Antibodies
10.3.5. Erythropoietin Stimulating Agents
10.3.6. Opioid Analgesics
10.3.7. Bisphosphonates
10.3.8. Granulocyte Colony Stimulating Factor
10.4. Market Attractiveness Analysis By Drug Class
11. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2019
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 - 2030
11.3.1. Lung Cancer
11.3.2. Breast Cancer
11.3.3. Prostate Cancer
11.3.4. Liver Cancer
11.3.5. Bladder Cancer
11.3.6. Leukemia
11.3.7. Ovarian Cancer
11.3.8. Melanoma
11.3.9. Others
11.4. Market Attractiveness Analysis By Indication
12. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel , 2015 - 2019
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 - 2030
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Compounding Pharmacies
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Region
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2019
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Regional Dynamics
14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
14.4.1. By Country
14.4.1.1. U.S.
14.4.1.2. Canada
14.4.2. By Drug Class
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
15. Latin America Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Regional Dynamics
15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
15.4.1. By Country
15.4.1.1. Brazil
15.4.1.2. Mexico
15.4.1.3. Rest of Latin America
15.4.2. By Drug Class
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Market Attractiveness Analysis
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
16. Europe Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Regional Dynamics
16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
16.4.1. By Country
16.4.1.1. Germany
16.4.1.2. Italy
16.4.1.3. France
16.4.1.4. U.K.
16.4.1.5. Spain
16.4.1.6. Russia
16.4.1.7. Rest of Europe
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Attractiveness Analysis
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
17. South Asia Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Regional Dynamics
17.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
17.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Malaysia
17.4.1.3. Indonesia
17.4.1.4. Thailand
17.4.1.5. Rest of South Asia
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
18. East Asia Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Regional Dynamics
18.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
18.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
18.4.1. By Country
18.4.1.1. China
18.4.1.2. Japan
18.4.1.3. South Korea
18.4.2. By Drug Class
18.4.3. By Indication
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
19. Oceania Market Analysis 2015-2019 and Forecast 2020-2030
19.1. Introduction
19.2. Regional Dynamics
19.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
19.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
19.4.1. By Country
19.4.1.1. Australia
19.4.1.2. New Zealand
19.4.2. By Drug Class
19.4.3. By Indication
19.4.4. By Distribution Channel
19.5. Market Attractiveness Analysis
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
20. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020-2030
20.1. Introduction
20.2. Regional Dynamics
20.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019
20.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
20.4.1. By Country
20.4.1.1. GCC Countries
20.4.1.2. South Africa
20.4.1.3. Rest of Middle East and Africa
20.4.2. By Drug Class
20.4.3. By Indication
20.4.4. By Distribution Channel
20.5. Market Attractiveness Analysis
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
21. Key and Emerging Countries Market Analysis 2015-2019 and Forecast 2020-2030
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Market Analysis
21.2.1. By Drug Class
21.2.2. By Indication
21.2.3. By Distribution Channel
21.3. Canada Market Analysis
21.3.1. By Drug Class
21.3.2. By Indication
21.3.3. By Distribution Channel
21.4. Mexico Market Analysis
21.4.1. By Drug Class
21.4.2. By Indication
21.4.3. By Distribution Channel
21.5. Brazil Market Analysis
21.5.1. By Drug Class
21.5.2. By Indication
21.5.3. By Distribution Channel
21.6. U.K. Market Analysis
21.6.1. By Drug Class
21.6.2. By Indication
21.6.3. By Distribution Channel
21.7. Germany Market Analysis
21.7.1. By Drug Class
21.7.2. By Indication
21.7.3. By Distribution Channel
21.8. France Market Analysis
21.8.1. By Drug Class
21.8.2. By Indication
21.8.3. By Distribution Channel
21.9. Italy Market Analysis
21.9.1. By Drug Class
21.9.2. By Indication
21.9.3. By Distribution Channel
21.10. Spain Market Analysis
21.10.1. By Drug Class
21.10.2. By Indication
21.10.3. By Distribution Channel
21.11. Russia Market Analysis
21.11.1. By Drug Class
21.11.2. By Indication
21.11.3. By Distribution Channel
21.12. China Market Analysis
21.12.1. By Drug Class
21.12.2. By Indication
21.12.3. By Distribution Channel
21.13. Japan Market Analysis
21.13.1. By Drug Class
21.13.2. By Indication
21.13.3. By Distribution Channel
21.14. South Korea Market Analysis
21.14.1. By Drug Class
21.14.2. By Indication
21.14.3. By Distribution Channel
21.15. India Market Analysis
21.15.1. By Drug Class
21.15.2. By Indication
21.15.3. By Distribution Channel
21.16. Thailand Market Analysis
21.16.1. By Drug Class
21.16.2. By Indication
21.16.3. By Distribution Channel
21.17. Indonesia Market Analysis
21.17.1. By Drug Class
21.17.2. By Indication
21.17.3. By Distribution Channel
21.18. Malaysia Market Analysis
21.18.1. By Drug Class
21.18.2. By Indication
21.18.3. By Distribution Channel
21.19. Australia Market Analysis
21.19.1. By Drug Class
21.19.2. By Indication
21.19.3. By Distribution Channel
21.20. New Zealand Market Analysis
21.20.1. By Drug Class
21.20.2. By Indication
21.20.3. By Distribution Channel
21.21. GCC Countries Market Analysis
21.21.1. By Drug Class
21.21.2. By Indication
21.21.3. By Distribution Channel
21.22. South Africa Market Analysis
21.22.1. By Drug Class
21.22.2. By Indication
21.22.3. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies (Cancer Supportive Care Products)
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1. By Regional Footprint of Players
22.4.2. Product Footprint by Players
22.4.3. Channel Footprint by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Pricing Analysis by Competition
23.3. Competition Benchmarking
23.4. Competition Deep Dive
23.4.1. Amgen, Inc.
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Sales Footprint
23.4.1.4. Analyst commentary
23.4.2. Johnson & Johnson Private Limited
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Sales Footprint
23.4.2.4. Analyst commentary
23.4.3. Baxter
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Sales Footprint
23.4.3.4. Analyst commentary
23.4.4. Merck
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Sales Footprint
23.4.4.4. Analyst commentary
23.4.5. Heron Pharma
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Sales Footprint
23.4.5.4. Analyst commentary
23.4.6. Tesaro
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Sales Footprint
23.4.6.4. Analyst commentary
23.4.7. Enlivity Corporation
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Sales Footprint
23.4.7.4. Analyst commentary
23.4.8. AmerisourceBergen Corporation (ASD Healthcare)
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Sales Footprint
23.4.8.4. Analyst commentary
23.4.9. Veru, Inc.
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Sales Footprint
23.4.9.4. Analyst commentary
23.4.10. ARIAD Pharmaceuticals, Inc.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Sales Footprint
23.4.10.4. Analyst commentary
23.4.11. Bendalis GmbH
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Sales Footprint
23.4.11.4. Analyst commentary
23.4.12. Helsinn Healthcare
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Sales Footprint
23.4.12.4. Analyst commentary
23.4.13. Novartis AG
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Sales Footprint
23.4.13.4. Analyst commentary
23.4.14. Hoffmann-La Roche Ltd
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Sales Footprint
23.4.14.4. Analyst commentary
23.4.15. Fagron
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Sales Footprint
23.4.15.4. Analyst commentary
23.4.16. Teva Pharmaceutical Industries Ltd.
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Sales Footprint
23.4.16.4. Analyst commentary
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Supportive Care Products Market
